XORTX Therapeutics receives Nasdaq notice for non-compliance
Source: SeekingAlpha
2025-04-18 02:45:56 ET
Late stage clinical pharmaceutical company XORTX Therapeutics ( NASDAQ: XRTX ) received notification from the Nasdaq that it is not in compliance with the minimum bid price requirement since the closing bid price for the company's common shares listed on Nasdaq was below US$1.00 for 30 consecutive business days....
Read the full article on Seeking Alpha
For further details see:
XORTX Therapeutics receives Nasdaq notice for non-compliance
XORTX Therapeutics Inc.
NASDAQ: XRTX
XRTX Trading
-11.26% G/L:
$0.4082 Last:
51,735 Volume:
$0.441 Open:
XRTX Latest News
March 13, 2026 07:00:00 am
XORTX Reports that Independent Proxy Advisory Firms Recommend XORTX Shareholders Vote "For" the Share Consolidation
March 05, 2026 07:00:00 am
XORTX Announces Filing and Mailing of the Meeting Documents in Connection with the Annual and Special Meeting of Shareholders
February 04, 2026 06:00:00 pm
XORTX Provides Update on Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems
December 31, 2025 06:15:00 pm
XORTX Announces Pioneering Research on Genome-Wide Pathogenic Pathways in Gout and Provides a Corporate Update
XRTX Stock Data
$2,854,975
6,704,616
0.29%
8
N/A
Biotechnology & Life Sciences
Healthcare
CA
Calgary
